Echo IQ announced positive interim results from its clinical trial at St Vincent's Hospital in Melbourne, Australia. The study demonstrates that the artificial intelligence in Echo's IQ's EchoSolv TM for Aortic Stenosis ("EchoSolv TM) enhances the identification of severe aortic stenosis (AS) using echocardiography. Echo IQ's EchoSolvTM platform for the detection of severe aortic stenosis was applied retrospectively to echocardiography ("echo") data from the hospital.

The results of the EchoSolv TM platform were compared with the cardiologist reports and clinical outcomes of patients. The trial's primary objective was to evaluate whether EchoSolv TM could enhance identification of patients with severe AS and help guide doctors to make active management plans for these patients. EchoSolvTM successfully identified 100% of patients with guideline-defined severe aortic stenosis (being 317, or 3.8%, of the study population of 8,257 patients attending the hospital's echo laboratory).

EchoSolvTM showed its capability to enhance clinical practice as 142 (or 45%) of those patients identified with guideline-severe AS by EchoSolv TM had not been identified as having guideline-severe AS by the cardiologist. EchoSolvTM identified an additional 145 patients (1.8% of the total study population) with a medium-high probability of severe AS but falling outside current clinical practice guidelines for a severe AS diagnosis. These patients would benefit from further review by the cardiologist.

This study demonstrates the potential for EchoSolvTM to play an important "decision support" role in echo reporting because of the major influence a diagnosis of severe AS has on subsequent management. The echo report issued by the cardiologist has a substantial impact on valve intervention decisions. Where severe AS had been reported by the cardiologist, patients went on to receive aortic valve replacements in 57% of cases.

Where the patient had not initially been identified as having disease of this severity by the cardiologist only 23% of cases underwent valve intervention. Severe AS is a serious condition with a high risk of death if left untreated, so identifying all patients with severe AS is of great importance. EchoSolv TM therefore shows strong promise by successfully highlighting all patients with guideline-severe AS to the reporting cardiologist, to assist with decision- making.